<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Prev Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Prev Cardiol</journal-id><journal-id journal-id-type="publisher-id">CPR</journal-id><journal-id journal-id-type="hwp">spcpr</journal-id><journal-title-group><journal-title>European Journal of Preventive Cardiology</journal-title></journal-title-group><issn pub-type="ppub">2047-4873</issn><issn pub-type="epub">2047-4881</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6146311</article-id><article-id pub-id-type="doi">10.1177/2047487318790722</article-id><article-id pub-id-type="publisher-id">10.1177_2047487318790722</article-id><article-categories><subj-group subj-group-type="heading"><subject>Obesity</subject><subj-group subj-group-type="heading"><subject>Full Research Paper</subject></subj-group></subj-group></article-categories><title-group><article-title>The relation between body fat distribution, plasma concentrations of
adipokines and the metabolic syndrome in patients with clinically manifest
vascular disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schrover</surname><given-names>Ilse M</given-names></name><xref ref-type="aff" rid="aff1-2047487318790722">1</xref></contrib><contrib contrib-type="author"><name><surname>van der Graaf</surname><given-names>Yolanda</given-names></name><xref ref-type="aff" rid="aff2-2047487318790722">2</xref></contrib><contrib contrib-type="author"><name><surname>Spiering</surname><given-names>Wilko</given-names></name><xref ref-type="aff" rid="aff1-2047487318790722">1</xref></contrib><contrib contrib-type="author"><name><surname>Visseren</surname><given-names>Frank LJ</given-names></name><xref ref-type="aff" rid="aff1-2047487318790722">1</xref><xref ref-type="corresp" rid="corresp1-2047487318790722"/></contrib><on-behalf-of>on behalf of the SMART study group</on-behalf-of></contrib-group><aff id="aff1-2047487318790722"><label>1</label>Department of Vascular Medicine,
University Medical Center Utrecht, The Netherlands</aff><aff id="aff2-2047487318790722"><label>2</label>Julius Center for Health Sciences and
Primary Care, University Medical Center Utrecht, The Netherlands</aff><author-notes><corresp id="corresp1-2047487318790722">Frank LJ Visseren, Department of Vascular
Medicine, University Medical Center Utrecht, Room F.02.126, PO Box 85500, 3508
GA Utrecht, The Netherlands. Email:
<email>f.l.j.visseren@umcutrecht.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2018</year></pub-date><volume>25</volume><issue>14</issue><fpage>1548</fpage><lpage>1557</lpage><history><date date-type="received"><day>21</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The European Society of Cardiology 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder content-type="society">European Society of
Cardiology</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec><title>Introduction</title><p>We evaluated the relationship between adipokine plasma concentrations and
body fat distribution and the metabolic syndrome.</p></sec><sec><title>Methods</title><p>In a cohort of 1215 patients with clinically manifest vascular disease the
relation between subcutaneous adipose tissue, visceral adipose tissue, waist
circumference, body mass index and plasma concentrations of adipsin,
chemerin, monocyte chemoattractant protein-1, migration inhibitory factor,
nerve growth factor, resistin, plasma amyloid A1, adiponectin, leptin,
plasminogen activator inhibitor-1 and hepatic growth factor were
cross-sectionally assessed with linear regression and adjusted for age and
gender. The relation between adipokines and the metabolic syndrome was
cross-sectionally evaluated using logistic regression. An adipokine profile
was developed to measure the effect of combined rather than single
adipokines.</p></sec><sec><title>Results</title><p>Adiposity was related to higher nerve growth factor, hepatic growth factor,
migration inhibitory factor, leptin and adipsin and with lower chemerin,
plasminogen activator inhibitor-1, resistin, plasma amyloid A1 and
adiponectin. The strongest positive relations were between body mass index
and adipsin (&#x003b2; 0.247; 95% CI 0.137&#x02013;0.356) and leptin (&#x003b2; 0.266; 95% CI
0.207&#x02013;0.324); the strongest negative relations were between body mass index
and plasma amyloid A1 (&#x003b2; &#x02013;0.266; 95% CI &#x02013;0.386 to &#x02013;0.146) and visceral
adipose tissue and adiponectin (&#x003b2; &#x02013;0.168; 95% CI &#x02013;0.226 to &#x02013;0.111). There
was no relation between subcutaneous adipose tissue and adipokines. Odds for
the metabolic syndrome were higher with each 1 SD higher hepatic growth
factor (OR 1.21; 95% CI 1.06&#x02013;1.38) and leptin (OR 1.26; 95% CI 1.10&#x02013;1.45)
and lower with each 1 SD higher adiponectin (OR 0.73; 95% CI 0.64&#x02013;0.83) and
resistin (OR 0.85; 95% CI 0.74&#x02013;0.97). The adipokine profile was related to
the metabolic syndrome (OR 1.03; 95% CI 1.00&#x02013;1.06).</p></sec><sec><title>Conclusion</title><p>Plasma concentrations of adipokines are related to obesity and body fat
distribution. The relation between adipokine concentrations and the
metabolic syndrome is independent of visceral adipose tissue.</p></sec></abstract><kwd-group><kwd>Obesity</kwd><kwd>visceral adipose tissue</kwd><kwd>subcutaneous adipose tissue</kwd><kwd>BMI</kwd><kwd>waist circumference</kwd><kwd>adipokines</kwd><kwd>metabolic syndrome</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-2047487318790722"><title>Introduction</title><p>The quantity of adipose tissue is a major driver of adipose tissue dysfunction (ATD)
leading to metabolic derangements such as insulin resistance, low-grade
inflammation, dyslipidaemia and elevated blood pressure.<sup><xref rid="bibr1-2047487318790722" ref-type="bibr">1</xref></sup> Although 10&#x02013;40% of the obese population is metabolically healthy, they have a
higher risk of subclinical and clinical atherosclerosis than normal weight
metabolically healthy individuals.<sup><xref rid="bibr2-2047487318790722" ref-type="bibr">2</xref>,<xref rid="bibr3-2047487318790722" ref-type="bibr">3</xref></sup> On the other hand, 5&#x02013;8% of the
healthy weight population is &#x02018;metabolically obese&#x02019;.<sup><xref rid="bibr4-2047487318790722" ref-type="bibr">4</xref>,<xref rid="bibr5-2047487318790722" ref-type="bibr">5</xref></sup> This can be explained by the
fact that ATD may also be present in the absence of obesity.<sup><xref rid="bibr4-2047487318790722" ref-type="bibr">4</xref>,<xref rid="bibr5-2047487318790722" ref-type="bibr">5</xref></sup> Apparently, ATD in an individual
who is considered to be at healthy weight may also lead to metabolic changes,
ultimately leading to the development of the metabolic syndrome, diabetes mellitus
type 2 (DM2) and cardiovascular disease.<sup><xref rid="bibr4-2047487318790722" ref-type="bibr">4</xref>,<xref rid="bibr5-2047487318790722" ref-type="bibr">5</xref></sup> Adipose tissue dysfunction is
characterised by an imbalance between the production of pro and anti- inflammatory
adipokines. These adipokines can either be produced by adipocytes or by the vascular
stromal fraction in adipose tissue, containing macrophages,<sup><xref rid="bibr6-2047487318790722" ref-type="bibr">6</xref></sup> contributing to insulin resistance and endothelial dysfunction.<sup><xref rid="bibr7-2047487318790722" ref-type="bibr">7</xref></sup> As a consequence, metabolic risk factors such as hypertriglyceridaemia, low
high-density lipoprotein cholesterol and chronic low-grade inflammation occur, being
causal factors in the development of cardiovascular disease and DM2.<sup><xref rid="bibr8-2047487318790722" ref-type="bibr">8</xref>,<xref rid="bibr9-2047487318790722" ref-type="bibr">9</xref></sup> Pathophysiological mechanisms
that underlie the development of ATD in the absence of obesity are exogenous factors
such as physical inactivity<sup><xref rid="bibr10-2047487318790722" ref-type="bibr">10</xref>,<xref rid="bibr11-2047487318790722" ref-type="bibr">11</xref></sup> and the dietary intake of saturated fat,<sup><xref rid="bibr12-2047487318790722" ref-type="bibr">12</xref>,<xref rid="bibr13-2047487318790722" ref-type="bibr">13</xref></sup> as well as
endogenous susceptibility such as a low birth weight,<sup><xref rid="bibr14-2047487318790722" ref-type="bibr">14</xref></sup> genetic predisposition<sup><xref rid="bibr15-2047487318790722" ref-type="bibr">15</xref></sup> and sympathetic nervous system activity.<sup><xref rid="bibr16-2047487318790722" ref-type="bibr">16</xref></sup></p><p>As ATD exists most abundantly, but not exclusively, in patients with obesity, the
production of adipokines is not likely to be totally dependent on adipose tissue
quantity. However, plasma levels of many pro-inflammatory adipokines such as chemerin,<sup><xref rid="bibr17-2047487318790722" ref-type="bibr">17</xref></sup> retinol-binding protein-4,<sup><xref rid="bibr18-2047487318790722" ref-type="bibr">18</xref></sup> leptin,<sup><xref rid="bibr19-2047487318790722" ref-type="bibr">19</xref></sup> lipocalin-2 and monocyte chemoattractant protein 1 (MCP-1)<sup><xref rid="bibr20-2047487318790722" ref-type="bibr">20</xref></sup> and the anti-inflammatory adipokine adiponectin<sup><xref rid="bibr18-2047487318790722" ref-type="bibr">18</xref>,<xref rid="bibr21-2047487318790722" ref-type="bibr">21</xref>,<xref rid="bibr22-2047487318790722" ref-type="bibr">22</xref></sup> are related to general
adiposity as well as to intra-abdominal fat. Upper body subcutaneous fat could be a
new adipose tissue depot of interest, because this is related to arterial stiffness.<sup><xref rid="bibr23-2047487318790722" ref-type="bibr">23</xref></sup> Higher concentrations of chemerin<sup><xref rid="bibr24-2047487318790722" ref-type="bibr">24</xref></sup> and leptin,<sup><xref rid="bibr25-2047487318790722" ref-type="bibr">25</xref>,<xref rid="bibr26-2047487318790722" ref-type="bibr">26</xref></sup> and lower concentrations of adiponectin<sup><xref rid="bibr27-2047487318790722" ref-type="bibr">27</xref></sup> are associated with the presence of the metabolic syndrome and cardiovascular
disease.</p><p>In the present study we evaluated the relation between plasma concentrations of 11
adipokines and different measures of general adiposity (body mass index (BMI), waist
circumference (WC)) and body fat distribution (subcutaneous adipose tissue (SAT) and
visceral adipose tissue (VAT)) and the metabolic syndrome in a cohort of patients
with clinically manifest vascular disease.</p></sec><sec sec-type="materials|methods" id="sec2-2047487318790722"><title>Materials and methods</title><sec id="sec3-2047487318790722"><title>Study design and patients</title><p>The study cohort consisted of patients participating in the Second Manifestations
of ARTerial disease-Magnetic Resonance (SMART-MR) study, a prospective study in
patients with clinically manifest vascular disease. Details of the design and
participants have been described elsewhere.<sup><xref rid="bibr28-2047487318790722" ref-type="bibr">28</xref>,<xref rid="bibr29-2047487318790722" ref-type="bibr">29</xref></sup> In brief, between May 2001
and December 2005, patients newly referred to the University Medical Center
Utrecht with recent (i.e. within 6 months prior to inclusion) manifest vascular
disease, coronary artery disease (CAD), cerebrovascular disease (CVD),
peripheral arterial disease (PAD) or an aortic abdominal aneurysm (AAA) were
invited to participate. CAD was defined as a recent diagnosis of angina
pectoris, myocardial infarction or coronary revascularisation. CVD was defined
as a recent diagnosis of ischaemic stroke, transient ischaemic attack or
amaurosis fugax. PAD was defined as a recent clinical diagnosis of PAD (Fontaine
stage 2, 3 or 4). For each patient, the presence or absence of the metabolic
syndrome was determined. We defined the metabolic syndrome according to the
National Cholesterol Education Program criteria<sup><xref rid="bibr30-2047487318790722" ref-type="bibr">30</xref></sup> as the presence of three or more of the following characteristics: WC
greater than 102&#x02009;cm (men) or greater than 88&#x02009;cm (women); triglycerides
1.7&#x02009;mmol/L or greater; high-density lipoprotein less than 1.29&#x02009;mmol/L (women) or
less than 1.00&#x02009;mmol/L (men); blood pressure 130/85&#x02009;mmHg or greater; fasting
glucose 5.6&#x02009;mmol/L or greater.</p><p>AAA was defined as an abdominal aortic aneurysm of 3.0&#x02009;cm or greater or recent
abdominal aortic surgery. Patients with terminal malignant disease, those not
independent in daily activities and not sufficiently fluent in Dutch were not
included. The medical ethics committee approved the study and all patients gave
written informed consent. After inclusion, patients underwent a standardised
vascular screening including measurements of the vascular risk factors,
non-invasive measurement of subclinical atherosclerosis and magnetic resonance
imaging of the brain. Risk factors, medical history and functioning were
assessed with questionnaires that the patients completed prior to their visit. A
total of 1309 patients with clinically manifest vascular disease were included
in the SMART-MR study, in 1215 of whom adipokine concentrations and adiposity
measurements were available and eligible for cross-sectional analyses.</p></sec><sec id="sec4-2047487318790722"><title>Adiposity measurements</title><p>BMI, WC, SAT and VAT were measured in this cohort. BMI was calculated by weight
(kg)/height (m)<sup><xref rid="bibr2-2047487318790722" ref-type="bibr">2</xref></sup>. WC was measured halfway between the lower rib and the iliac crest in a
standing position. B-mode ultrasound of the abdomen was obtained to measure
visceral and subcutaneous adipose tissue and was performed by well-trained
registered vascular technologists in a certified vascular laboratory.
Ultrasonographic measurements were performed in a supine position using an ATL
HDI 3000 ultrasound device (Philips Medical Systems, Eindhoven, The Netherlands)
with a C4-2 transducer. There was no bowel preparation performed before the
ultrasound measurement. VAT was ultrasonographically measured as the distance
between the peritoneum and the lumbar spine using electronic callipers. A strict
protocol was used, including the position of the transducer and pressure applied
on the transducer. The transducer was placed in a straight line drawn between
the left and right midpoints of the lower rib and the iliac crest. Measurements
were performed at the end of a quiet expiration, applying minimal pressure
without displacement or compression of the abdominal cavity. The distance was
measured three times at slightly different positions; the VAT was calculated as
the mean value of these three measurements. Previously, the ultrasound protocol
for measuring VAT was validated with computed tomography (CT) at our centre.<sup><xref rid="bibr31-2047487318790722" ref-type="bibr">31</xref></sup> Ultrasonographic measurements were strongly associated with CT
measurements of VAT; Pearson&#x02019;s correlation coefficient was 0.81
(<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). Also, an interobserver coefficient of
variation of 5.4% was found for ultrasound measurements of VAT, indicating good
reproducibility. For determining subcutaneous fat, the distance between the
linea alba and the skin was measured. Abdominal muscles were thus excluded for
intra-abdominal and subcutaneous fat measurements.</p></sec><sec id="sec5-2047487318790722"><title>Measurement of plasma concentrations of adipokines</title><p>Adipokines were measured in plasma which had been stored at &#x02013;80&#x000b0; celsius within
hours after collection. The plasma concentrations of the adipocytokines MCP-1,
nerve growth factor (NGF), hepatic growth factor (HGF), migration inhibitory
factor (MIF), adiponectin, adipsin, chemerin, resistin, plasma amyloid A1
(SAA1), plasminogen activator inhibitor 1 (PAI-1), interferon gamma inducible
protein-10 (IP-10) and leptin were measured with a microbead-based Luminex
multiplex immunoassay (Bio-Rad, Munich, Germany). These specific adipokines were
chosen for their effects on different (patho)physiological mechanisms;
inflammation, coagulation and glucose metabolism. Fluorophore-labelled
microbeads were coated with specific monoclonal antibodies against the
aforementioned proteins. The beads coated with capture antibodies were used
together with secondary biotinylated antibodies. Measurements and data analysis
of all assays were performed on the Bioplex system in combination with Bioplex
manager software (Biorad). The multiplex immunoassay results correlated
significantly with enzyme-linked immunosorbent assay measurements. All adipokine
concentrations were reported in ng/L. The analysis protocol as well as the
characteristics of the assay have been published previously.<sup><xref rid="bibr32-2047487318790722" ref-type="bibr">32</xref></sup> Plasma high-sensitivity C-reactive protein (hsCRP) was measured by
immunonephelometry (Nephelometer Analyzer BN II; Dade-Behring, Marburg, Germany)
with a lower detection limit of the test of 0.2&#x02009;mg/l. As high CRP concentrations
may have a different pathophysiological origin than low-grade inflammation, as
seen in obesity and vascular diseases, individuals with CRP concentrations
greater than 15&#x02009;mg/L (<italic>n</italic>&#x02009;=&#x02009;53) were excluded from the analyses.
Insulin sensitivity was calculated with the homeostasis model assessment of
insulin resistance (HOMA-IR) with the formula: [fasting insulin (mU/l) * fasting
glucose (mmol/l)]/22.5. HOMA-IR was not calculated in patients using exogenous
insulin.</p></sec><sec id="sec6-2047487318790722"><title>Data analyses</title><p>Mean and standard deviation (SD) are reported if continuous variables were
normally distributed and median and interquartile range if distributions were
skewed. Categorical variables are expressed as percentages (numbers).
Concentrations of adipokines were log-transformed, due to a skewed distribution.
The relation between measures of adiposity and adipokine concentrations was
quantified with linear regression analyses. As IP-10 showed a skewed
distribution even after log-transformation, this adipokine was only used in the
&#x02018;adipokine profile&#x02019;. Results are expressed as beta regression coefficients (&#x003b2;)
and 95% confidence intervals (CIs) denoting the change in adipokine
concentration per SD increase in adiposity measurements. Three models were used
to estimate this relation. Firstly, a model was made without adjustments for the
potential confounders. Secondly, a model was made with adjustments for the
potential confounders gender and age. In the third model, additional adjustments
were made for current smoking, lipid-lowering therapy, history of DM2 and
hsCRP.</p><p>The relation between adipokines and (characteristics of&#x02009;) the metabolic syndrome
was assessed with logistic regression analysis. As we hypothesise that the
metabolic syndrome is the consequence of the combination of various pro and
anti-inflammatory adipokines, rather than the effect of single adipokines, we
developed an &#x02018;adipokine profile&#x02019;. The adipokine profile was constructed weighing
all adipokines equally and not taking into account their correlations, not
aiming on predicting individual risk, but being hypothesis generating. All
adipokines were divided into quartiles, patients in the most favourable quartile
regarding cardiovascular risk received 1 point, patients in the least favourable
quartile received 4 points. As this was performed for all patients with all 11
adipokines, a profile from 11 to 44 was possible. Also, the relation between
single adipokines and (characteristics of) the metabolic syndrome was assessed.
Results are expressed as odds ratios (ORs) with 95% CIs. For these analyses,
only data from patients without DM2 were used, because DM2 can be regarded as an
ultimate consequence of the metabolic syndrome and would therefore influence the
results. Two models were used, an unadjusted model and a model adjusted for age
and gender. No other additional adjustments were performed, because possible
confounders (such as hsCRP) can also be seen as intermediates in the relation
between adipokines and the metabolic syndrome. To reduce bias and to improve
statistical efficiency, missing values for visceral fat thickness
(<italic>n</italic>&#x02009;=&#x02009;8), subcutaneous fat thickness
(<italic>n</italic>&#x02009;=&#x02009;21), BMI (<italic>n</italic>&#x02009;=&#x02009;1), WC
(<italic>n</italic>&#x02009;=&#x02009;52), smoking status (<italic>n</italic>&#x02009;=&#x02009;9) and estimated
glomerular filtration rate (<italic>n</italic>&#x02009;=&#x02009;14) were completed in the
dataset by single regression imputation.</p></sec></sec><sec sec-type="results" id="sec7-2047487318790722"><title>Results</title><sec id="sec8-2047487318790722"><title>Baseline characteristics</title><p>Baseline characteristics in tertiles of WC are presented in <xref rid="table1-2047487318790722" ref-type="table">Table 1</xref>. Data are
gender pooled because WC cut-off points are different for men and women. The
population was predominantly men (80%) and the mean age was 59&#x02009;&#x000b1;&#x02009;10 years. In
concordance with an increase in WC over tertiles, a rise in BMI, VAT and SAT was
seen, as well as an increase in the prevalence of the metabolic syndrome,
hypertension, elevated triglycerides and elevated fasting glucose
concentrations. <table-wrap id="table1-2047487318790722" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline characteristics according to tertiles of waist
circumference.</p></caption><alternatives><graphic specific-use="table1-2047487318790722" xlink:href="10.1177_2047487318790722-table1"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Tertile 1 (<italic>n</italic>&#x02009;=&#x02009;394)</th><th rowspan="1" colspan="1">Tertile 2 (<italic>n</italic>&#x02009;=&#x02009;393)</th><th rowspan="1" colspan="1">Tertile 3 (<italic>n</italic>&#x02009;=&#x02009;367)</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">Waist circumference cm (mean range)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Men<sup>a</sup></td><td rowspan="1" colspan="1">87 (70&#x02013;92)</td><td rowspan="1" colspan="1">97 (93&#x02013;101)</td><td rowspan="1" colspan="1">109 (102&#x02013;133)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Women<sup>a</sup></td><td rowspan="1" colspan="1">76 (59&#x02013;84)</td><td rowspan="1" colspan="1">89 (85&#x02013;93)</td><td rowspan="1" colspan="1">102 (94&#x02013;127)</td></tr><tr><td rowspan="1" colspan="1">Male gender (%)</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">82</td><td rowspan="1" colspan="1">80</td></tr><tr><td rowspan="1" colspan="1">Age (years)<sup>a</sup></td><td rowspan="1" colspan="1">58&#x02009;&#x000b1;&#x02009;10</td><td rowspan="1" colspan="1">59&#x02009;&#x000b1;&#x02009;10</td><td rowspan="1" colspan="1">60&#x02009;&#x000b1;&#x02009;9</td></tr><tr><td rowspan="1" colspan="1">Current smoking (%)</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">40</td></tr><tr><td rowspan="1" colspan="1">Medical history</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Peripheral artery disease (%)</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">19</td></tr><tr><td rowspan="1" colspan="1">&#x02003;AAA (%)</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cerebral artery disease (%)</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">22</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Coronary artery disease (%)</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">70</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Diabetes mellitus type 2 (%)</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">24</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)<sup>a</sup></td><td rowspan="1" colspan="1">24.0&#x02009;&#x000b1;&#x02009;2.5</td><td rowspan="1" colspan="1">26.4&#x02009;&#x000b1;&#x02009;2.1</td><td rowspan="1" colspan="1">30.5&#x02009;&#x000b1;&#x02009;3.5</td></tr><tr><td rowspan="1" colspan="1">Subcutaneous adipose tissue (cm)<sup>a</sup></td><td rowspan="1" colspan="1">2.2&#x02009;&#x000b1;&#x02009;1.2</td><td rowspan="1" colspan="1">2.5&#x02009;&#x000b1;&#x02009;1.3</td><td rowspan="1" colspan="1">2.8&#x02009;&#x000b1;&#x02009;1.5</td></tr><tr><td rowspan="1" colspan="1">Visceral adipose tissue (cm)<sup>a</sup></td><td rowspan="1" colspan="1">7.7&#x02009;&#x000b1;&#x02009;1.8</td><td rowspan="1" colspan="1">9.6&#x02009;&#x000b1;&#x02009;2.1</td><td rowspan="1" colspan="1">11.3&#x02009;&#x000b1;&#x02009;2.4</td></tr><tr><td rowspan="1" colspan="1">Systolic blood pressure (mmHg)<sup>a</sup></td><td rowspan="1" colspan="1">140&#x02009;&#x000b1;&#x02009;21</td><td rowspan="1" colspan="1">143&#x02009;&#x000b1;&#x02009;23</td><td rowspan="1" colspan="1">145&#x02009;&#x000b1;&#x02009;22</td></tr><tr><td rowspan="1" colspan="1">Diastolic blood pressure (mmHg)<sup>a</sup></td><td rowspan="1" colspan="1">81&#x02009;&#x000b1;&#x02009;11</td><td rowspan="1" colspan="1">82&#x02009;&#x000b1;&#x02009;12</td><td rowspan="1" colspan="1">84&#x02009;&#x000b1;&#x02009;12</td></tr><tr><td rowspan="1" colspan="1">Metabolic syndrome (%)</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">57</td></tr><tr><td rowspan="1" colspan="1">Total cholesterol (mmol/L)<sup>a</sup></td><td rowspan="1" colspan="1">4.8&#x02009;&#x000b1;&#x02009;1.0</td><td rowspan="1" colspan="1">4.9&#x02009;&#x000b1;&#x02009;1.0</td><td rowspan="1" colspan="1">5.0&#x02009;&#x000b1;&#x02009;1.0</td></tr><tr><td rowspan="1" colspan="1">Triglycerides (mmol/L)<sup>b</sup></td><td rowspan="1" colspan="1">1.2 (0.9&#x02013;1.7)</td><td rowspan="1" colspan="1">1.5 (1.2&#x02013;2.1)</td><td rowspan="1" colspan="1">1.7 (1.3&#x02013;2.4)</td></tr><tr><td rowspan="1" colspan="1">HDL-cholesterol (mmol/L)&#x02013;men<sup>a</sup></td><td rowspan="1" colspan="1">1.32&#x02009;&#x000b1;&#x02009;0.36</td><td rowspan="1" colspan="1">1.20&#x02009;&#x000b1;&#x02009;0.32</td><td rowspan="1" colspan="1">1.14&#x02009;&#x000b1;&#x02009;0.32</td></tr><tr><td rowspan="1" colspan="1">HDL-cholesterol (mmol/L)&#x02013;women<sup>a</sup></td><td rowspan="1" colspan="1">1.67&#x02009;&#x000b1;&#x02009;0.40</td><td rowspan="1" colspan="1">1.45&#x02009;&#x000b1;&#x02009;0.40</td><td rowspan="1" colspan="1">1.34&#x02009;&#x000b1;&#x02009;0.41</td></tr><tr><td rowspan="1" colspan="1">LDL-cholesterol (mmol/L)<sup>a</sup></td><td rowspan="1" colspan="1">2.8&#x02009;&#x000b1;&#x02009;0.9</td><td rowspan="1" colspan="1">2.8&#x02009;&#x000b1;&#x02009;0.9</td><td rowspan="1" colspan="1">2.9&#x02009;&#x000b1;&#x02009;0.9</td></tr><tr><td rowspan="1" colspan="1">eGFR (ml/min/1.73m<sup>2</sup>)<sup>a</sup></td><td rowspan="1" colspan="1">78&#x02009;&#x000b1;&#x02009;16</td><td rowspan="1" colspan="1">77&#x02009;&#x000b1;&#x02009;17</td><td rowspan="1" colspan="1">79&#x02009;&#x000b1;&#x02009;18</td></tr><tr><td rowspan="1" colspan="1">Insulin (mIU/L)<sup>b</sup></td><td rowspan="1" colspan="1">7 (5&#x02013;9)</td><td rowspan="1" colspan="1">10 (8&#x02013;14)</td><td rowspan="1" colspan="1">13 (10&#x02013;19)</td></tr><tr><td rowspan="1" colspan="1">HOMA-IR<sup>b</sup></td><td rowspan="1" colspan="1">1.80 (1.20&#x02013;2.49)</td><td rowspan="1" colspan="1">2.63 (1.97&#x02013;3.73)</td><td rowspan="1" colspan="1">3.64 (2.61&#x02013;6.14)</td></tr><tr><td rowspan="1" colspan="1">hs-CRP (mg/L)<sup>b</sup></td><td rowspan="1" colspan="1">1.3 (0.7&#x02013;3.0)</td><td rowspan="1" colspan="1">1.7 (0.8&#x02013;3.4)</td><td rowspan="1" colspan="1">2.7 (1.5&#x02013;4.9)</td></tr><tr><td rowspan="1" colspan="1">Glucose (mmol/L)<sup>a</sup></td><td rowspan="1" colspan="1">5.8&#x02009;&#x000b1;&#x02009;1.3</td><td rowspan="1" colspan="1">6.2&#x02009;&#x000b1;&#x02009;1.5</td><td rowspan="1" colspan="1">6.8&#x02009;&#x000b1;&#x02009;2.0</td></tr><tr><td rowspan="1" colspan="1">Medication</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Antihypertensive medication (%)</td><td rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">85</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Glucose lowering medication (%)</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">17</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Lipid lowering medication (%)</td><td rowspan="1" colspan="1">69</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">71</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Platelet aggregation inhibition (%)</td><td rowspan="1" colspan="1">79</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">77</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-2047487318790722"><p>Data are presented as mean&#x02009;&#x000b1;&#x02009;SD<sup>a</sup> or as median plus
interquartile range,<sup>b</sup> unless otherwise indicated.
Waist circumference tertiles were separately determined for men
and women and thereafter pooled to provide an equal
sex-distribution over the tertiles.</p></fn><fn id="table-fn2-2047487318790722"><p>AAA: abdominal aorta aneurysm; BMI: body mass index; HDL:
high-density lipoprotein; LDL: low-density lipoprotein; eGFR:
glomerular filtration rate, estimated by the modification of
diet in renal disease (MDRD) equation; HOMA-IR: homeostasis
model of assessment&#x02013;insulin resistance; hs-CRP: high-sensitivity
C-reactive protein.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec9-2047487318790722"><title>Relation between total adiposity and fat distribution and plasma
concentrations of adipokines</title><p>Higher BMI, higher WC and higher VAT were all related to higher plasma
concentrations of the adipokines NGF, HGF, MIF, leptin and adipsin (<xref ref-type="fig" rid="fig1-2047487318790722">Figure 1</xref> and Supplementary
Table 1) after adjustment for the potential confounding factors age and gender.
The strongest positive relations were seen between BMI and adipsin (&#x003b2; 0.247; 95%
CI 0.137&#x02013;0.356) and between BMI and leptin (&#x003b2; 0.266; 95% CI 0.207&#x02013;0.324). There
were no or very weak relations between SAT and plasma concentrations of
adipokines (<xref ref-type="fig" rid="fig1-2047487318790722">Figure 1</xref> and
Supplementary Table 1). Adiposity was negatively related to chemerin, PAI-1,
resistin, SAA1 and adiponectin concentrations. The strongest negative relations
were seen between BMI and SAA1 (&#x003b2; &#x02013;0.266; 95% CI &#x02013;0.386 to &#x02013;0.146) and between
VAT and adiponectin (&#x003b2; &#x02013;0.168; 95% CI &#x02013;0.226 to &#x02013;0.111). Additional adjustment
for the confounding factors smoking, the use of lipid-lowering medication,
history of diabetes and hsCRP only marginally attenuated relations between
adiposity measurements and adipokine concentrations (<xref ref-type="fig" rid="fig1-2047487318790722">Figure 1</xref> and Supplementary Table 1).
There was no statistical interaction of DM2 in the relation between adiposity
measurements and adipokine concentrations (<italic>P</italic> values for
interaction &#x0003e;0.05). <fig id="fig1-2047487318790722" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Relations between adiposity measurements and adipokines. Results are
presented as regression coefficients (&#x003b2;) and 95% confidence
intervals (CIs) per 1 standard deviation (SD) increase in adiposity
measurements. Model II (open squares) is adjusted for age and
gender, model III (closed squares) is additionally adjusted for
current smoking, lipid-lowering therapy, history of diabetes type 2
and high-sensitivity C-reactive protein (hsCRP). BMI: body mass
index; WC: waist circumference; SAT: subcutaneous adipose tissue;
VAT: visceral adipose tissue; MCP-1: monocyte chemoattractant
protein 1; NGF: nerve growth factor; HGF: hepatic growth factor;
PAI-1: plasminogen activator inhibitor 1; MIF: migration inhibitory
factor; SAA1: serum amyloid A1.</p></caption><graphic xlink:href="10.1177_2047487318790722-fig1"/></fig></p></sec><sec id="sec10-2047487318790722"><title>Relation between adipokine profile and the metabolic syndrome</title><p>The adipokine profile ranged from 17 to 44, with a median score of 30
(interquartile range (IQR) 27&#x02013;33). A 1 point higher adipokine profile was
related to a higher risk of the metabolic syndrome (OR 1.03; 95% CI 1.00&#x02013;1.06)
adjusted for age and gender. Additional adjustment for VAT changed this relation
to a small extent (OR 1.02; 95% CI 0.99&#x02013;1.05). A sensitivity analysis including
only the male patients did not change the results.</p></sec><sec id="sec11-2047487318790722"><title>Relation between adipokine plasma concentrations and presence of the
metabolic syndrome</title><p>A 1 SD higher plasma concentration of HGF was related to a 21% higher risk of the
metabolic syndrome (OR 1.21; 95% CI 1.06&#x02013;1.38) adjusted for age and gender, and
a 26% higher risk for the metabolic syndrome was seen with each 1 SD higher
leptin concentration (OR 1.26; 95% CI 1.10&#x02013;1.45) in the analyses adjusted for
age and gender (<xref rid="table2-2047487318790722" ref-type="table">Table
2</xref>). A 1 SD higher concentration of adiponectin was related to a 27%
lower risk of the metabolic syndrome (OR 0.73; 95% CI 0.64&#x02013;0.83) and a 15% lower
risk of the metabolic syndrome was seen with each 1 SD higher resistin
concentration (OR 0.85; 95% CI 0.74&#x02013;0.97). <table-wrap id="table2-2047487318790722" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Relation between adipokines and presence of the metabolic
syndrome.</p></caption><alternatives><graphic specific-use="table2-2047487318790722" xlink:href="10.1177_2047487318790722-table2"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1">Model</th><th rowspan="1" colspan="1">Adipsin</th><th rowspan="1" colspan="1">Chemerin</th><th rowspan="1" colspan="1">MCP-1</th><th rowspan="1" colspan="1">MIF</th><th rowspan="1" colspan="1">NGF</th><th rowspan="1" colspan="1">Resistin</th><th rowspan="1" colspan="1">SAA1</th><th rowspan="1" colspan="1">Adiponectin</th><th rowspan="1" colspan="1">Leptin</th><th rowspan="1" colspan="1">PAI-1</th><th rowspan="1" colspan="1">HGF</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="2" colspan="1">I</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">0.91</td><td rowspan="1" colspan="1">1.08</td><td rowspan="1" colspan="1">1.05</td><td rowspan="1" colspan="1">1.12</td><td rowspan="1" colspan="1">
<bold>0.85*</bold>
</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">
<bold>0.72*</bold>
</td><td rowspan="1" colspan="1">
<bold>1.21*</bold>
</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">
<bold>1.20*</bold>
</td></tr><tr><td rowspan="1" colspan="1">(0.85&#x02013;1.09)</td><td rowspan="1" colspan="1">(0.80&#x02013;1.04)</td><td rowspan="1" colspan="1">(0.95&#x02013;1.23)</td><td rowspan="1" colspan="1">(0.92&#x02013;1.19)</td><td rowspan="1" colspan="1">(0.98&#x02013;1.27)</td><td rowspan="1" colspan="1">
<bold>(0.75&#x02013;0.97)</bold>
</td><td rowspan="1" colspan="1">(0.86&#x02013;1.11)</td><td rowspan="1" colspan="1">
<bold>(0.63&#x02013;0.83)</bold>
</td><td rowspan="1" colspan="1">
<bold>(1.06&#x02013;1.38)</bold>
</td><td rowspan="1" colspan="1">(0.83&#x02013;1.08)</td><td rowspan="1" colspan="1">
<bold>(1.05&#x02013;1.38)</bold>
</td></tr><tr><td rowspan="2" colspan="1">II</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">0.91</td><td rowspan="1" colspan="1">1.08</td><td rowspan="1" colspan="1">1.06</td><td rowspan="1" colspan="1">1.12</td><td rowspan="1" colspan="1">
<bold>0.85*</bold>
</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">
<bold>0.73*</bold>
</td><td rowspan="1" colspan="1">
<bold>1.26*</bold>
</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">
<bold>1.21*</bold>
</td></tr><tr><td rowspan="1" colspan="1">(0.85&#x02013;1.09)</td><td rowspan="1" colspan="1">(0.80&#x02013;1.03)</td><td rowspan="1" colspan="1">(0.95&#x02013;1.23)</td><td rowspan="1" colspan="1">(0.93&#x02013;1.21)</td><td rowspan="1" colspan="1">(0.99&#x02013;1.28)</td><td rowspan="1" colspan="1">
<bold>(0.74&#x02013;0.97)</bold>
</td><td rowspan="1" colspan="1">(0.86&#x02013;1.12)</td><td rowspan="1" colspan="1">
<bold>(0.64&#x02013;0.83)</bold>
</td><td rowspan="1" colspan="1">
<bold>(1.10&#x02013;1.45)</bold>
</td><td rowspan="1" colspan="1">(0.82&#x02013;1.07)</td><td rowspan="1" colspan="1">
<bold>(1.06&#x02013;1.38)</bold>
</td></tr><tr><td rowspan="2" colspan="1">III</td><td rowspan="1" colspan="1">
<bold>0.85*</bold>
</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">1.06</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">1.04</td><td rowspan="1" colspan="1">
<bold>0.85*</bold>
</td><td rowspan="1" colspan="1">1.11</td><td rowspan="1" colspan="1">
<bold>0.82*</bold>
</td><td rowspan="1" colspan="1">1.14</td><td rowspan="1" colspan="1">1.04</td><td rowspan="1" colspan="1">1.08</td></tr><tr><td rowspan="1" colspan="1">
<bold>(0.74&#x02013;0.98)</bold>
</td><td rowspan="1" colspan="1">(0.86&#x02013;1.14)</td><td rowspan="1" colspan="1">(0.92&#x02013;1.23)</td><td rowspan="1" colspan="1">(0.85&#x02013;1.13)</td><td rowspan="1" colspan="1">(0.90&#x02013;1.19)</td><td rowspan="1" colspan="1">
<bold>(0.73&#x02013;0.98)</bold>
</td><td rowspan="1" colspan="1">(0.96&#x02013;1.29)</td><td rowspan="1" colspan="1">
<bold>(0.71&#x02013;0.96)</bold>
</td><td rowspan="1" colspan="1">(0.98&#x02013;1.34)</td><td rowspan="1" colspan="1">(0.90&#x02013;1.20)</td><td rowspan="1" colspan="1">(0.93&#x02013;1.25)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-2047487318790722"><p>Data are presented as odds ratios (ORs) with 95% confidence
intervals (CIs) per 1 SD increase in adipokine concentrations.
*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn><fn id="table-fn4-2047487318790722"><p>MCP-1: monocyte chemoattractant protein 1; NGF: nerve growth
factor; HGF: hepatic growth factor; PAI-1: plasminogen activator
inhibitor 1; MIF: migration inhibitory factor; SAA1: serum
amyloid A1; model I: crude model; model II: adjusted for age and
gender; model III: additionally adjusted for visceral adipose
tissue.</p></fn></table-wrap-foot></table-wrap></p><p>No interaction was observed of VAT in the relation between adipokines and the
presence of the metabolic syndrome. In <xref rid="table3-2047487318790722" ref-type="table">Table 3</xref> the relation between a 1 SD
increase in adipokines and the metabolic syndrome stratified into quartiles of
VAT is shown, adjusted for age and gender. Additional adjustment for BMI, a
measure of general adiposity, did not change the results. <table-wrap id="table3-2047487318790722" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Association between adipokines and the metabolic syndrome, stratified
to quartiles of visceral adipose tissue.</p></caption><alternatives><graphic specific-use="table3-2047487318790722" xlink:href="10.1177_2047487318790722-table3"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1">Adipokine</th><th rowspan="1" colspan="1">Q1 (3.4&#x02013;7.5&#x02009;cm) OR (95% CI)</th><th rowspan="1" colspan="1">Q2 (7.6&#x02013;9.2&#x02009;cm) OR (95% CI)</th><th rowspan="1" colspan="1">Q3 (9.3&#x02013;11.1&#x02009;cm) OR (95% CI)</th><th rowspan="1" colspan="1">Q4 (11.2&#x02013;18.9&#x02009;cm) OR (95% CI)</th><th rowspan="1" colspan="1"><italic>P</italic> for interaction</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">MCP-1</td><td rowspan="1" colspan="1">0.76 (0.53&#x02013;1.08)</td><td rowspan="1" colspan="1">0.97 (0.68&#x02013;1.37)</td><td rowspan="1" colspan="1">1.03 (0.74&#x02013;1.44)</td><td rowspan="1" colspan="1">0.84 (0.62&#x02013;1.14)</td><td rowspan="1" colspan="1">0.49</td></tr><tr><td rowspan="1" colspan="1">NGF</td><td rowspan="1" colspan="1">0.81 (0.54&#x02013;1.21)</td><td rowspan="1" colspan="1">1.15 (0.79&#x02013;1.67)</td><td rowspan="1" colspan="1">1.25 (0.90&#x02013;1.72)</td><td rowspan="1" colspan="1">0.94 (0.70&#x02013;1.28)</td><td rowspan="1" colspan="1">0.36</td></tr><tr><td rowspan="1" colspan="1">HGF</td><td rowspan="1" colspan="1">0.94 (0.65&#x02013;1.35)</td><td rowspan="1" colspan="1">0.92 (0.62&#x02013;1.37)</td><td rowspan="1" colspan="1">1.05 (0.78&#x02013;1.40)</td><td rowspan="1" colspan="1">0.93 (0.66&#x02013;1.32)</td><td rowspan="1" colspan="1">0.84</td></tr><tr><td rowspan="1" colspan="1">PAI-1</td><td rowspan="1" colspan="1">0.96 (0.57&#x02013;1.61)</td><td rowspan="1" colspan="1">1.39 (0.93&#x02013;2.06)</td><td rowspan="1" colspan="1">0.93 (0.68&#x02013;1.28)</td><td rowspan="1" colspan="1">0.78 (0.59&#x02013;1.03)</td><td rowspan="1" colspan="1">0.94</td></tr><tr><td rowspan="1" colspan="1">MIF</td><td rowspan="1" colspan="1">1.18 (0.75&#x02013;1.85)</td><td rowspan="1" colspan="1">1.07 (0.71&#x02013;1.62)</td><td rowspan="1" colspan="1">1.09 (0.80&#x02013;1.47)</td><td rowspan="1" colspan="1">1.09 (0.77&#x02013;1.54)</td><td rowspan="1" colspan="1">0.70</td></tr><tr><td rowspan="1" colspan="1">Adipsin</td><td rowspan="1" colspan="1">0.99 (0.65&#x02013;1.50)</td><td rowspan="1" colspan="1">1.04 (0.71&#x02013;1.52)</td><td rowspan="1" colspan="1">0.85 (0.63&#x02013;1.15)</td><td rowspan="1" colspan="1">0.84 (0.63&#x02013;1.12)</td><td rowspan="1" colspan="1">0.15</td></tr><tr><td rowspan="1" colspan="1">Adiponectin</td><td rowspan="1" colspan="1">0.58 (0.35&#x02013;0.97)</td><td rowspan="1" colspan="1">0.68 (0.45&#x02013;1.03)</td><td rowspan="1" colspan="1">0.64 (0.45&#x02013;0.91)</td><td rowspan="1" colspan="1">0.76 (0.57&#x02013;1.01)</td><td rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">Resistin</td><td rowspan="1" colspan="1">0.62 (0.38&#x02013;1.00)</td><td rowspan="1" colspan="1">0.95 (0.64&#x02013;1.40)</td><td rowspan="1" colspan="1">0.84 (0.63&#x02013;1.12)</td><td rowspan="1" colspan="1">0.88 (0.68&#x02013;1.16)</td><td rowspan="1" colspan="1">0.21</td></tr><tr><td rowspan="1" colspan="1">Chemerin</td><td rowspan="1" colspan="1">0.91 (0.59&#x02013;1.41)</td><td rowspan="1" colspan="1">1.02 (0.70&#x02013;1.49)</td><td rowspan="1" colspan="1">0.83 (0.59&#x02013;1.15)</td><td rowspan="1" colspan="1">0.86 (0.64&#x02013;1.16)</td><td rowspan="1" colspan="1">0.18</td></tr><tr><td rowspan="1" colspan="1">SAA1</td><td rowspan="1" colspan="1">0.84 (0.56&#x02013;1.27)</td><td rowspan="1" colspan="1">1.27 (0.83&#x02013;1.93)</td><td rowspan="1" colspan="1">1.01 (0.72&#x02013;1.40)</td><td rowspan="1" colspan="1">0.79 (0.60&#x02013;1.05)</td><td rowspan="1" colspan="1">0.40</td></tr><tr><td rowspan="1" colspan="1">Leptin</td><td rowspan="1" colspan="1">0.88 (0.56&#x02013;1.40)</td><td rowspan="1" colspan="1">1.43 (0.97&#x02013;2.11)</td><td rowspan="1" colspan="1">1.00 (0.70&#x02013;1.43)</td><td rowspan="1" colspan="1">0.90 (0.66&#x02013;1.23)</td><td rowspan="1" colspan="1">0.71</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn5-2047487318790722"><p>Results are presented as odds ratios (ORs) with 95% confidence
intervals (CIs) for the presence of the metabolic syndrome with
a 1 SD increase in adipokines, stratified into quartiles of
visceral adipose tissue (VAT, in cm).</p></fn><fn id="table-fn6-2047487318790722"><p><italic>P</italic> value for interaction is the interaction of
continuous measured VAT in the relation between adipokines and
the metabolic syndrome.</p></fn><fn id="table-fn7-2047487318790722"><p>MCP-1: monocyte chemoattractant protein 1; NGF: nerve growth
factor; HGF: hepatic growth factor; PAI-1: plasminogen activator
inhibitor 1; MIF: migration inhibitory factor; SAA1: serum
amyloid A.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec sec-type="discussion" id="sec12-2047487318790722"><title>Discussion</title><p>In this study, it is demonstrated that general and visceral adiposity, but not
subcutaneous adiposity, are related to plasma concentrations of adipokines in
patients with clinically manifest vascular disease. The newly developed adipokine
profile and several single adipokine plasma concentrations are related to the
presence of the metabolic syndrome. This relation was partly sustained even after
adjustment for adiposity, indicating that adipose tissue (dys)function (as reflected
by the adipokine profile) is more important than the quantity of adipose tissue in
the relation with the metabolic syndrome.</p><sec id="sec13-2047487318790722"><title>Relation between adiposity and adipokine concentrations</title><p>The pro-inflammatory adipokines NGF, MIF and adipsin were related to general and
abdominal adiposity, which was shown in various earlier studies.<sup><xref rid="bibr17-2047487318790722" ref-type="bibr">17</xref><xref rid="bibr18-2047487318790722" ref-type="bibr"/>&#x02013;<xref rid="bibr19-2047487318790722" ref-type="bibr">19</xref>,<xref rid="bibr21-2047487318790722" ref-type="bibr">21</xref>,<xref rid="bibr22-2047487318790722" ref-type="bibr">22</xref></sup> This is in line with the
concept that an increase in adipose tissue quantity causes a shift in the
balance between the production of pro and anti-inflammatory adipokines,
resulting in an excess of pro-inflammatory adipokines. However, some relations
between adiposity measurements and adipokines in our study were unexpected in
the light of this line of reasoning. This was the case for the negative
relations of adiposity and the adipokines SAA1, chemerin and resistin, which are
believed to be pro-inflammatory.<sup><xref rid="bibr33-2047487318790722" ref-type="bibr">33</xref>,<xref rid="bibr34-2047487318790722" ref-type="bibr">34</xref></sup> Index-event bias could
explain this phenomenon. In the present study patients were all diagnosed with
clinically evident atherosclerotic disease, in contrast to the patients included
in previous studies. This inverse relation has been shown before. Chemerin was
negatively related to VAT in patients with hepatic steatosis, suggesting a
modulating function of chemerin in the link between insulin resistance and steatosis.<sup><xref rid="bibr35-2047487318790722" ref-type="bibr">35</xref></sup> A similar function of chemerin in atherosclerotic patients could be
present, explaining the negative relation between VAT and chemerin. Also, in a
general population with approximately 10% DM2, an inverse association between
anthropometric measurements and resistin plasma levels was found.<sup><xref rid="bibr36-2047487318790722" ref-type="bibr">36</xref></sup> As SAA1 is a lipoprotein, the extensive use of lipid-lowering therapy in
our cohort could (although we corrected for the use of lipid-lowering
medication) influence the results. Index-event bias could also explain the
negative relation between adiposity and the pro-coagulant PAI-1 we found,
contrary to results in the earlier literature. These unexpected results limit
the generalisability of our study and emphasise the possibility of different
associations in patients with already diagnosed cardiovascular disease.</p><p>Also shown in earlier studies<sup><xref rid="bibr21-2047487318790722" ref-type="bibr">21</xref>,<xref rid="bibr37-2047487318790722" ref-type="bibr">37</xref></sup> we found general and
abdominal adiposity to be related to the procoagulant adipokine HGF, the glucose
metabolism influencing adipokine leptin and, negatively, to the
anti-inflammatory adipokine adiponectin. No relations between subcutaneous
adipose tissue and adipokines were found, indicative of the more important role
of VAT in the development of DM2 and atherosclerotic disease.</p></sec><sec id="sec14-2047487318790722"><title>Adipokine profile and the metabolic syndrome</title><p>As the metabolic syndrome consists of different pathophysiological components and
is the result of various metabolic derangements potentially caused by different
adipokines, we decided to combine the individual effects of adipokines in an
adipokine profile. There was a significant relation between this profile and the
presence of the metabolic syndrome, even after adjustment for visceral
adiposity. This indicates an effect of adipose tissue (dys)function beyond
quantity. Apparently, the function of adipose tissue is more important than the
quantity with respect to the metabolic consequences leading to disease such as
DM2 and vascular diseases.</p></sec><sec id="sec15-2047487318790722"><title>Single adipokines and metabolic syndrome</title><p>With respect to the relations between individual adipokines and the metabolic
syndrome, we found leptin and HGF to be positively related to the metabolic
syndrome. The positive relation between plasma concentrations of leptin and the
metabolic syndrome has been demonstrated in patients with the metabolic syndrome.<sup><xref rid="bibr38-2047487318790722" ref-type="bibr">38</xref></sup> Elevated leptin concentrations are related to both WC<sup><xref rid="bibr35-2047487318790722" ref-type="bibr">35</xref>,<xref rid="bibr39-2047487318790722" ref-type="bibr">39</xref></sup> and
insulin resistance, even in euglycemic patients.<sup><xref rid="bibr40-2047487318790722" ref-type="bibr">40</xref></sup> The relation between HGF and the metabolic syndrome was previously also
shown in 1474 healthy subjects.<sup><xref rid="bibr41-2047487318790722" ref-type="bibr">41</xref></sup> Of the metabolic syndrome characteristics, HGF is most likely to
influence blood pressure, because it mediates remodelling of the vascular wall.<sup><xref rid="bibr42-2047487318790722" ref-type="bibr">42</xref></sup> An association between HGF and insulin resistance has also been reported.<sup><xref rid="bibr41-2047487318790722" ref-type="bibr">41</xref></sup></p><p>As expected, higher concentrations of adiponectin decreased the odds for the
presence of the metabolic syndrome. As shown in various studies,<sup><xref rid="bibr38-2047487318790722" ref-type="bibr">38</xref>,<xref rid="bibr43-2047487318790722" ref-type="bibr">43</xref></sup> higher
adiponectin is associated with lower pro-inflammatory adipokine concentrations,
and consequently the absence of adipose tissue dysfunction. Interestingly,
recent Mendelian randomisation studies show a counterintuitive association
between higher adiponectin levels and cardiovascular mortality<sup><xref rid="bibr44-2047487318790722" ref-type="bibr">44</xref></sup> but also lower adiponectin levels being associated with an increased risk
of the metabolic syndrome and hyperglycaemia.<sup><xref rid="bibr45-2047487318790722" ref-type="bibr">45</xref></sup></p><p>Surprisingly, higher concentrations of the pro-inflammatory resistin also
decreased the odds for the metabolic syndrome. In healthy individuals, resistin
is positively associated with insulin sensitivity.<sup><xref rid="bibr36-2047487318790722" ref-type="bibr">36</xref></sup> Paradoxically, in patients with low-grade inflammation or patients with
atherosclerosis the resistin plasma level is elevated.<sup><xref rid="bibr34-2047487318790722" ref-type="bibr">34</xref>,<xref rid="bibr46-2047487318790722" ref-type="bibr">46</xref></sup> As our cohort comprised
patients with cardiovascular disease, we expected resistin concentrations to
relate positively to the metabolic syndrome. There is some suggestion in the
literature that certain classes of antihypertensive drugs could decrease
resistin concentrations,<sup><xref rid="bibr47-2047487318790722" ref-type="bibr">47</xref></sup> which could explain our results.</p><p>The absence of interaction of VAT in the relation between adipokines and the
metabolic syndrome again emphasises the role of adipose tissue function rather
than quantity in the development of metabolic derangements, despite losing
statistical significance when correcting for VAT in the relation between
adipokines and the metabolic syndrome (<xref rid="table2-2047487318790722" ref-type="table">Table 2</xref>). However, it should be noted
that changes in plasma concentrations of adipokines could also be the result of
metabolic changes.</p></sec><sec id="sec16-2047487318790722"><title>Limitations and strengths</title><p>The strengths of our study include the large cohort and the number of adipokines
that were measured. Moreover, our cohort provides real-world data of a
clinically relevant group of patients. Also, some study limitations should be
considered. The limitations include that the cohort consisted of patients with
clinically manifest vascular disease, which may limit generalisability to
patients without vascular disease. No data were available on the physical
activity or dietary intake of patients, which could influence the results,
because little activity and a high intake of saturated fatty acids can cause the
metabolic syndrome, even in lean individuals.<sup><xref rid="bibr48-2047487318790722" ref-type="bibr">48</xref></sup> Also, as the measurement of plasmatic adipokines is not current practice,
there is no current implementation of this study in general practice. Moreover,
although we adjusted for several potential confounders in the multivariable
analyses, there may be residual confounding. As this was a cross-sectional study
one should be cautious in making causal inferences.</p></sec></sec><sec sec-type="conclusions" id="sec17-2047487318790722"><title>Conclusion</title><p>In conclusion, general adiposity and visceral adiposity are related to plasma
concentrations of adipokines that reflect adipose tissue (dys)function. Adipokine
concentrations are related to the presence of the metabolic syndrome, independent of
the amount of VAT. Therefore, adipose tissue dysfunction and not adiposity per se
are likely to be the causal link between (abdominal) adiposity and metabolic changes
causing the metabolic syndrome, eventually leading to DM2 and vascular disease.</p></sec><sec id="sec18-2047487318790722"><title>Members of the SMART study group</title><p>A Algra; Y van der Graaf; DE Grobbee; GEHM Rutten, Julius Center for Health Sciences
and Primary Care; FLJ Visseren, Department of Internal Medicine; GJ de Borst,
Department of Vascular Surgery; LJ Kappelle, Department of Neurology; T Leiner,
Department of Radiology; HM Nathoe, Department of Cardiology.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="Table_s1.pdf" orientation="portrait" id="d35e1395" position="anchor"/></supplementary-material></sec></body><back><sec id="sec19-2047487318790722"><title>Author contribution</title><p>IMS, FLJV and WS contributed to the conception or design of the work. YvdG
contributed to the acquisition, analysis or interpretation of data for the work. IMS
drafted the manuscript. FLJV, WS and YvdG critically revised the manuscript. All
authors gave final approval and agree to be accountable for all aspects of the work
ensuring integrity and accuracy.</p></sec><sec id="sec20-2047487318790722"><title>Declaration of conflicting interests</title><p>The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p></sec><sec id="sec21-2047487318790722"><title>Funding</title><p>The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p></sec><ref-list><title>References</title><ref id="bibr1-2047487318790722"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>C</given-names></name><name><surname>Massaro</surname><given-names>J</given-names></name><name><surname>Hoffmann</surname><given-names>U</given-names></name><etal>et al.</etal></person-group>
<article-title>Abdominal visceral and subcutaneous adipose tissue compartments:
association with metabolic risk factors in the Framingham Heart
Study</article-title>. <source>Circulation</source>
<year>2007</year>; <volume>116</volume>:
<fpage>39</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">17576866</pub-id></mixed-citation></ref><ref id="bibr2-2047487318790722"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caleyachetty</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>GN</given-names></name><name><surname>Toulis</surname><given-names>KA</given-names></name><etal>et al.</etal></person-group>
<article-title>Metabolically healthy obese and incident cardiovascular disease
events among 3.5 million men and women</article-title>. <source>J Am Coll
Cardiol</source>
<year>2017</year>; <volume>70</volume>:
<fpage>1429</fpage>&#x02013;<lpage>1437</lpage>.<pub-id pub-id-type="pmid">28911506</pub-id></mixed-citation></ref><ref id="bibr3-2047487318790722"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TJ</given-names></name><name><surname>Shin</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><etal>et al.</etal></person-group>
<article-title>Metabolically healthy obesity and the risk for subclinical
atherosclerosis</article-title>. <source>Atherosclerosis</source>
<year>2017</year>; <volume>262</volume>:
<fpage>191</fpage>&#x02013;<lpage>197</lpage>.<pub-id pub-id-type="pmid">28385392</pub-id></mixed-citation></ref><ref id="bibr4-2047487318790722"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Primeau</surname><given-names>V</given-names></name><name><surname>Coderre</surname><given-names>L</given-names></name><name><surname>Karelis</surname><given-names>aD</given-names></name><etal>et al.</etal></person-group>
<article-title>Characterizing the profile of obese patients who are
metabolically healthy</article-title>. <source>Int J Obes
[Internet]</source>
<year>2011</year>; <volume>35</volume>: <fpage>971</fpage>&#x02013;<lpage>981</lpage>.
<comment><ext-link ext-link-type="uri" xlink:href="www.nature.com/doifinder/10.1038/ijo.2010.216">www.nature.com/doifinder/10.1038/ijo.2010.216</ext-link> (accessed 9
July 2018)</comment>.</mixed-citation></ref><ref id="bibr5-2047487318790722"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>KM</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Choi</surname><given-names>HY</given-names></name><etal>et al.</etal></person-group>
<article-title>Higher mortality in metabolically obese normal-weight people than
in metabolically healthy obese subjects in elderly Koreans</article-title>.
<source>Clin Endocrinol (Oxf)</source>
<year>2013</year>; <volume>79</volume>:
<fpage>364</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">23330616</pub-id></mixed-citation></ref><ref id="bibr6-2047487318790722"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kralova Lesna</surname><given-names>I</given-names></name><name><surname>Petras</surname><given-names>M</given-names></name><name><surname>Cejkova</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Cardiovascular disease predictors and adipose tissue macrophage
polarization: Is there a link?</article-title>
<source>Eur J Prev Cardiol</source>
<year>2018</year>; <volume>25</volume>:
<fpage>328</fpage>&#x02013;<lpage>334</lpage>.<pub-id pub-id-type="pmid">29154680</pub-id></mixed-citation></ref><ref id="bibr7-2047487318790722"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajer</surname><given-names>GR</given-names></name><name><surname>Van Haeften</surname><given-names>TW</given-names></name><name><surname>Visseren</surname><given-names>FLJ</given-names></name></person-group>
<article-title>Adipose tissue dysfunction in obesity, diabetes,
and vascular diseases</article-title>. <source>Eur Heart J</source>
<year>2008</year>; <volume>29</volume>:
<fpage>2959</fpage>&#x02013;<lpage>2971</lpage>.<pub-id pub-id-type="pmid">18775919</pub-id></mixed-citation></ref><ref id="bibr8-2047487318790722"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kip</surname><given-names>KE</given-names></name><name><surname>Marroquin</surname><given-names>OC</given-names></name><name><surname>Kelley</surname><given-names>DE</given-names></name><etal>et al.</etal></person-group>
<article-title>Clinical importance of obesity versus the metabolic syndrome in
cardiovascular risk in women: a report from the Women&#x02019;s Ischemia Syndrome
Evaluation (WISE) Study</article-title>. <source>Circulation</source>
<year>2004</year>; <volume>109</volume>:
<fpage>706</fpage>&#x02013;<lpage>713</lpage>.<pub-id pub-id-type="pmid">14970104</pub-id></mixed-citation></ref><ref id="bibr9-2047487318790722"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voulgari</surname><given-names>C</given-names></name><name><surname>Tentolouris</surname><given-names>N</given-names></name><name><surname>Dilaveris</surname><given-names>P</given-names></name><etal>et al.</etal></person-group>
<article-title>Increased heart failure risk in normal-weight people with
metabolic syndrome compared with metabolically healthy obese
individuals</article-title>. <source>J Am Coll Cardiol</source>
<year>2011</year>; <volume>58</volume>:
<fpage>1343</fpage>&#x02013;<lpage>1350</lpage>.<pub-id pub-id-type="pmid">21920263</pub-id></mixed-citation></ref><ref id="bibr10-2047487318790722"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>CY</given-names></name><name><surname>Lokken</surname><given-names>RP</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><etal>et al.</etal></person-group>
<article-title>Physical activity of moderate intensity and risk of type 2
diabetes: a systematic review</article-title>. <source>Diabetes
Care</source>
<year>2007</year>; <volume>30</volume>:
<fpage>744</fpage>&#x02013;<lpage>752</lpage>.<pub-id pub-id-type="pmid">17327354</pub-id></mixed-citation></ref><ref id="bibr11-2047487318790722"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rana</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>TY</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><etal>et al.</etal></person-group>
<article-title>Adiposity compared with physical inactivity and risk of type 2
diabetes in women</article-title>. <source>Diabetes Care</source>
<year>2007</year>; <volume>30</volume>:
<fpage>53</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">17192333</pub-id></mixed-citation></ref><ref id="bibr12-2047487318790722"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cnop</surname><given-names>M</given-names></name></person-group>
<article-title>Fatty acids and glucolipotoxicity in the
pathogenesis of type 2 diabetes</article-title>. <source>Biochem Soc Trans
[Internet]</source>
<year>2008</year>; <volume>36</volume>(<issue>Pt 3</issue>):
<fpage>348</fpage>&#x02013;<lpage>352</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="www.ncbi.nlm.nih.gov/pubmed/18481955">www.ncbi.nlm.nih.gov/pubmed/18481955</ext-link> (accessed 9 July
2018)</comment>.</mixed-citation></ref><ref id="bibr13-2047487318790722"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galgani</surname><given-names>JE</given-names></name><name><surname>Uauy</surname><given-names>RD</given-names></name><name><surname>Aguirre</surname><given-names>CA</given-names></name><etal>et al.</etal></person-group>
<article-title>Effect of the dietary fat quality on insulin
sensitivity</article-title>. <source>Br J Nutr [Internet]</source>
<year>2008</year>; <volume>100</volume>: <fpage>471</fpage>&#x02013;<lpage>479</lpage>.
<comment><ext-link ext-link-type="uri" xlink:href="www.journals.cambridge.org/abstract_S0007114508894408">www.journals.cambridge.org/abstract_S0007114508894408</ext-link>
(accessed 9 July 2018)</comment>.</mixed-citation></ref><ref id="bibr14-2047487318790722"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freathy</surname><given-names>RM</given-names></name><name><surname>Bennett</surname><given-names>AJ</given-names></name><name><surname>Ring</surname><given-names>SM</given-names></name><etal>et al.</etal></person-group>
<article-title>Type 2 diabetes risk alleles are associated with reduced size at
birth</article-title>. <source>Diabetes</source>
<year>2009</year>; <volume>58</volume>:
<fpage>1428</fpage>&#x02013;<lpage>1433</lpage>.<pub-id pub-id-type="pmid">19228808</pub-id></mixed-citation></ref><ref id="bibr15-2047487318790722"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stan&#x0010d;&#x000e1;kov&#x000e1;</surname><given-names>A</given-names></name><name><surname>Kuulasmaa</surname><given-names>T</given-names></name><name><surname>Paananen</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<article-title>Association of 18 confirmed susceptibility loci for type 2
diabetes with indices of insulin release, proinsulin conversion, and insulin
sensitivity in 5,327 nondiabetic Finnish men</article-title>.
<source>Diabetes</source>
<year>2009</year>; <volume>58</volume>:
<fpage>2129</fpage>&#x02013;<lpage>2136</lpage>.<pub-id pub-id-type="pmid">19502414</pub-id></mixed-citation></ref><ref id="bibr16-2047487318790722"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emdin</surname><given-names>M</given-names></name><name><surname>Gastaldelli</surname><given-names>A</given-names></name><name><surname>Muscelli</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<article-title>Hyperinsulinemia and autonomic nervous system dysfunction in
obesity: effects of weight loss</article-title>.
<source>Circulation</source>
<year>2001</year>; <volume>103</volume>:
<fpage>513</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">11157715</pub-id></mixed-citation></ref><ref id="bibr17-2047487318790722"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfadda</surname><given-names>AA</given-names></name><name><surname>Sallam</surname><given-names>RM</given-names></name><name><surname>Chishti</surname><given-names>MA</given-names></name><etal>et al.</etal></person-group>
<article-title>Differential patterns of serum concentration and adipose tissue
expression of chemerin in obesity: adipose depot specificity and gender
dimorphism</article-title>. <source>Mol Cells</source>
<year>2012</year>; <volume>33</volume>:
<fpage>591</fpage>&#x02013;<lpage>596</lpage>.<pub-id pub-id-type="pmid">22544171</pub-id></mixed-citation></ref><ref id="bibr18-2047487318790722"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhie</surname><given-names>YJ</given-names></name><name><surname>Choi</surname><given-names>B-M</given-names></name><name><surname>Eun</surname><given-names>SH</given-names></name><etal>et al.</etal></person-group>
<article-title>Association of serum retinol binding protein 4 with adiposity and
pubertal development in Korean children and adolescents</article-title>.
<source>J Korean Med Sci [Internet]</source>
<year>2011</year>; <volume>26</volume>: <fpage>797</fpage>&#x02013;<lpage>802</lpage>.
<comment><ext-link ext-link-type="uri" xlink:href="www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3102875&#x00026;tool=pmcentrez&#x00026;rendertype=abstract">www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3102875&#x00026;tool=pmcentrez&#x00026;rendertype=abstract</ext-link>
(accessed 9 July 2018)</comment>.</mixed-citation></ref><ref id="bibr19-2047487318790722"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano</surname><given-names>HMS</given-names></name><name><surname>Carvalho</surname><given-names>GQ</given-names></name><name><surname>Pereira</surname><given-names>PF</given-names></name><etal>et al.</etal></person-group>
<article-title>Body composition, biochemical and clinical changes of adolescents
with excessive adiposity</article-title>. <source>Arq Bras Cardiol</source>
<year>2010</year>; <volume>95</volume>:
<fpage>464</fpage>&#x02013;<lpage>472</lpage>.<pub-id pub-id-type="pmid">20721518</pub-id></mixed-citation></ref><ref id="bibr20-2047487318790722"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Jung</surname><given-names>ES</given-names></name><etal>et al.</etal></person-group>
<article-title>Visceral adiposity and the severity of coronary artery disease in
middle-aged subjects with normal waist circumference and its relation with
lipocalin-2 and MCP-1</article-title>. <source>Atherosclerosis</source>
<year>2010</year>; <volume>213</volume>:
<fpage>592</fpage>&#x02013;<lpage>597</lpage>.<pub-id pub-id-type="pmid">20947088</pub-id></mixed-citation></ref><ref id="bibr21-2047487318790722"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YL</given-names></name><name><surname>Kim</surname><given-names>TK</given-names></name><name><surname>Cheong</surname><given-names>ES</given-names></name><etal>et al.</etal></person-group>
<article-title>Relation of absolute or relative adiposity to insulin resistance,
retinol binding protein-4, leptin, and adiponectin in type 2
diabetes</article-title>. <source>Diabetes Metab J</source>
<year>2012</year>; <volume>36</volume>:
<fpage>415</fpage>&#x02013;<lpage>421</lpage>.<pub-id pub-id-type="pmid">23275935</pub-id></mixed-citation></ref><ref id="bibr22-2047487318790722"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaibi</surname><given-names>GQ</given-names></name><name><surname>Cruz</surname><given-names>ML</given-names></name><name><surname>Weigensberg</surname><given-names>MJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Adiponectin independently predicts metabolic syndrome in
overweight Latino youth</article-title>. <source>J Clin Endocrinol
Metab</source>
<year>2007</year>; <volume>92</volume>:
<fpage>1809</fpage>&#x02013;<lpage>1813</lpage>.<pub-id pub-id-type="pmid">17311859</pub-id></mixed-citation></ref><ref id="bibr23-2047487318790722"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantin</surname><given-names>F</given-names></name><name><surname>Comellato</surname><given-names>G</given-names></name><name><surname>Rossi</surname><given-names>AP</given-names></name><etal>et al.</etal></person-group>
<article-title>Relationship between neck circumference, insulin resistance and
arterial stiffness in overweight and obese subjects</article-title>.
<source>Eur J Prev Cardiol</source>
<year>2017</year>; <volume>24</volume>:
<fpage>1532</fpage>&#x02013;<lpage>1540</lpage>.<pub-id pub-id-type="pmid">28728486</pub-id></mixed-citation></ref><ref id="bibr24-2047487318790722"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jialal</surname><given-names>I</given-names></name><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<article-title>Increased chemerin and decreased omentin-1 in both adipose tissue
and plasma in nascent metabolic syndrome</article-title>. <source>J Clin
Endocrinol Metab</source>
<year>2013</year>; <volume>98</volume>:
<fpage>E514</fpage>&#x02013;<lpage>E517</lpage>.<pub-id pub-id-type="pmid">23303213</pub-id></mixed-citation></ref><ref id="bibr25-2047487318790722"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ntyintyane</surname><given-names>L</given-names></name><name><surname>Panz</surname><given-names>V</given-names></name><name><surname>Raal</surname><given-names>FJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Leptin, adiponectin, and high-sensitivity C-reactive protein in
relation to the metabolic syndrome in urban South African blacks with and
without coronary artery disease</article-title>. <source>Metab Syndr Relat
Disord</source>
<year>2009</year>; <volume>7</volume>:
<fpage>243</fpage>&#x02013;<lpage>248</lpage>.<pub-id pub-id-type="pmid">19462476</pub-id></mixed-citation></ref><ref id="bibr26-2047487318790722"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taneli</surname><given-names>F</given-names></name><name><surname>Yegane</surname><given-names>S</given-names></name><name><surname>Ulman</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<article-title>Increased serum leptin concentrations in patients with chronic
stable angina pectoris and ST-elevated myocardial
infarction</article-title>. <source>Angiology [Internet]</source>
<year>2006</year>; <volume>57</volume>: <fpage>267</fpage>&#x02013;<lpage>272</lpage>.
<comment><ext-link ext-link-type="uri" xlink:href="www.scopus.com/inward/record.uri?eid=2-s2.0-33745529478&#x00026;partnerID=40&#x00026;md5=cdb6d7a62ad36d66870f747aa3f16099">www.scopus.com/inward/record.uri?eid=2-s2.0-33745529478&#x00026;partnerID=40&#x00026;md5=cdb6d7a62ad36d66870f747aa3f16099</ext-link>
(accessed 9 July 2018)</comment>.</mixed-citation></ref><ref id="bibr27-2047487318790722"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>
<article-title>Implications of plasma concentrations of adiponectin in patients
with coronary artery disease</article-title>. <source>Heart</source>
<year>2004</year>; <volume>90</volume>:
<fpage>528</fpage>&#x02013;<lpage>533</lpage>.<pub-id pub-id-type="pmid">15084551</pub-id></mixed-citation></ref><ref id="bibr28-2047487318790722"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geerlings</surname><given-names>MI</given-names></name><name><surname>Appelman</surname><given-names>APA</given-names></name><name><surname>Vincken</surname><given-names>KL</given-names></name><etal>et al.</etal></person-group>
<article-title>Brain volumes and cerebrovascular lesions on MRI in patients with
atherosclerotic disease. The SMART-MR study</article-title>.
<source>Atherosclerosis [Internet]</source>
<year>2010</year>; <volume>210</volume>:
<fpage>130</fpage>&#x02013;<lpage>136</lpage>.</mixed-citation></ref><ref id="bibr29-2047487318790722"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simons</surname><given-names>PCG</given-names></name><name><surname>Algra</surname><given-names>A</given-names></name><name><surname>Van De Laak</surname><given-names>MF</given-names></name><etal>et al.</etal></person-group>
<article-title>Second manifestations of ARTerial disease (SMART) study:
rationale and design</article-title>. <source>Eur J Epidemiol</source>
<year>1999</year>; <volume>15</volume>:
<fpage>773</fpage>&#x02013;<lpage>781</lpage>.<pub-id pub-id-type="pmid">10608355</pub-id></mixed-citation></ref><ref id="bibr30-2047487318790722"><label>30</label><mixed-citation publication-type="journal"><collab>Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults</collab>.
<article-title>Executive summary of the third report of the National
Cholesterol Education Program Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel
III)</article-title>. <source>JAMA</source>
<year>2001</year>; <volume>285</volume>:
<fpage>2486</fpage>&#x02013;<lpage>2497</lpage>.<pub-id pub-id-type="pmid">11368702</pub-id></mixed-citation></ref><ref id="bibr31-2047487318790722"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Wink</surname><given-names>O</given-names></name><name><surname>Zelissen</surname><given-names>PM</given-names></name><etal>et al.</etal></person-group>
<article-title>Validity and reproducibility of ultrasonography for the
measurement of intra-abdominal adipose tissue</article-title>. <source>Int J
Obes Relat Metab Disord</source>
<year>2001</year>; <volume>25</volume>:
<fpage>1346</fpage>&#x02013;<lpage>1351</lpage>.<pub-id pub-id-type="pmid">11571598</pub-id></mixed-citation></ref><ref id="bibr32-2047487318790722"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schipper</surname><given-names>HS</given-names></name><name><surname>De Jager</surname><given-names>W</given-names></name><name><surname>Van Dijk</surname><given-names>MEA</given-names></name><etal>et al.</etal></person-group>
<article-title>A multiplex immunoassay for human adipokine
profiling</article-title>. <source>Clin Chem</source>
<year>2010</year>; <volume>56</volume>:
<fpage>1320</fpage>&#x02013;<lpage>1328</lpage>.<pub-id pub-id-type="pmid">20530731</pub-id></mixed-citation></ref><ref id="bibr33-2047487318790722"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozaoglu</surname><given-names>K</given-names></name><name><surname>Bolton</surname><given-names>K</given-names></name><name><surname>McMillan</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<article-title>Chemerin is a novel adipokine associated with obesity and
metabolic syndrome</article-title>. <source>Endocrinology</source>
<year>2007</year>; <volume>148</volume>:
<fpage>4687</fpage>&#x02013;<lpage>4694</lpage>.<pub-id pub-id-type="pmid">17640997</pub-id></mixed-citation></ref><ref id="bibr34-2047487318790722"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>MP</given-names></name><name><surname>Lehrke</surname><given-names>M</given-names></name><name><surname>Wolfe</surname><given-names>ML</given-names></name><etal>et al.</etal></person-group>
<article-title>Resistin is an inflammatory marker of atherosclerosis in
humans</article-title>. <source>Circulation</source>
<year>2005</year>; <volume>111</volume>:
<fpage>932</fpage>&#x02013;<lpage>939</lpage>.<pub-id pub-id-type="pmid">15710760</pub-id></mixed-citation></ref><ref id="bibr35-2047487318790722"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekaert</surname><given-names>M</given-names></name><name><surname>Ouwens</surname><given-names>DM</given-names></name><name><surname>H&#x000f6;rbelt</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<article-title>Reduced expression of chemerin in visceral adipose tissue
associates with hepatic steatosis in patients with obesity</article-title>.
<source>Obesity</source>
<year>2016</year>; <volume>24</volume>:
<fpage>2544</fpage>&#x02013;<lpage>2552</lpage>.<pub-id pub-id-type="pmid">27768254</pub-id></mixed-citation></ref><ref id="bibr36-2047487318790722"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dom&#x000ed;nguez Coello</surname><given-names>S</given-names></name><name><surname>Cabrera de Le&#x000f3;n</surname><given-names>A</given-names></name><name><surname>Almeida Gonz&#x000e1;lez</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>
<article-title>Inverse association between serum resistin and insulin resistance
in humans</article-title>. <source>Diabetes Res Clin Pract</source>
<year>2008</year>; <volume>82</volume>:
<fpage>256</fpage>&#x02013;<lpage>261</lpage>.<pub-id pub-id-type="pmid">18789551</pub-id></mixed-citation></ref><ref id="bibr37-2047487318790722"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaess</surname><given-names>BM</given-names></name><name><surname>Pedley</surname><given-names>A</given-names></name><name><surname>Massaro</surname><given-names>JM</given-names></name><etal>et al.</etal></person-group>
<article-title>Relation of vascular growth factors with CT-derived measures of
body fat distribution: the Framingham Heart Study</article-title>. <source>J
Clin Endocrinol Metab</source>
<year>2012</year>; <volume>97</volume>:
<fpage>987</fpage>&#x02013;<lpage>994</lpage>.<pub-id pub-id-type="pmid">22170711</pub-id></mixed-citation></ref><ref id="bibr38-2047487318790722"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bremer</surname><given-names>AA</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name></person-group>
<article-title>Adipose tissue dysfunction in nascent metabolic
syndrome</article-title>. <source>J Obesity</source>
<year>2013</year>; <volume>2013</volume>:
<fpage>393142</fpage>&#x02013;<lpage>393142</lpage>.</mixed-citation></ref><ref id="bibr39-2047487318790722"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingelsson</surname><given-names>E</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><etal>et al.</etal></person-group>
<article-title>Circulating ghrelin, leptin, and soluble leptin receptor
concentrations and cardiometabolic risk factors in a community-based
sample</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2008</year>; <volume>93</volume>:
<fpage>3149</fpage>&#x02013;<lpage>3157</lpage>.<pub-id pub-id-type="pmid">18492761</pub-id></mixed-citation></ref><ref id="bibr40-2047487318790722"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcelino Rodr&#x000ed;guez</surname><given-names>I</given-names></name><name><surname>Oliva Garc&#x000ed;a</surname><given-names>J</given-names></name><name><surname>Alem&#x000e1;n S&#x000e1;nchez</surname><given-names>JJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Lipid and inflammatory biomarker profiles in early insulin
resistance</article-title>. <source>Acta Diabetol [Internet]</source>
<year>2016</year>; <volume>53</volume>: <fpage>905</fpage>&#x02013;<lpage>913</lpage>.
<pub-id pub-id-type="doi">10.1007/s00592-016-0885-6</pub-id><comment> (accessed 9 July
2018)</comment>.</mixed-citation></ref><ref id="bibr41-2047487318790722"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiratsuka</surname><given-names>A</given-names></name><name><surname>Adachi</surname><given-names>H</given-names></name><name><surname>Fujiura</surname><given-names>Y</given-names></name><etal>et al.</etal></person-group>
<article-title>Strong association between serum hepatocyte growth factor and
metabolic syndrome</article-title>. <source>J Clin Endocrinol Metab
[Internet]</source>
<year>2005</year>; <volume>90</volume>: <fpage>2927</fpage>&#x02013;<lpage>2931</lpage>.
<comment><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/15713721%5Cnfile:///C:/DocumentsandSettings/maya/Misdocumentos/QUIROZ2DOCTORADO/ARTICULODEREVISIONDOCTORADO/2005">http://www.ncbi.nlm.nih.gov/pubmed/15713721%5Cnfile:///C:/DocumentsandSettings/maya/Mis
documentos/QUIROZ 2 DOCTORADO/ARTICULO DE REVISION
DOCTORADO/2005</ext-link> (accessed 9 July
2018)</comment>.</mixed-citation></ref><ref id="bibr42-2047487318790722"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yl&#x000e4;-Herttuala</surname><given-names>S</given-names></name><name><surname>Rissanen</surname><given-names>TT</given-names></name><name><surname>Vajanto</surname><given-names>I</given-names></name><etal>et al.</etal></person-group>
<article-title>Vascular endothelial growth factors: biology and current status
of clinical applications in cardiovascular medicine</article-title>.
<source>J Am Coll Cardiol</source>
<year>2007</year>; <volume>49</volume>:
<fpage>1015</fpage>&#x02013;<lpage>1026</lpage>.<pub-id pub-id-type="pmid">17349880</pub-id></mixed-citation></ref><ref id="bibr43-2047487318790722"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>J</given-names></name><name><surname>McQuillan</surname><given-names>BM</given-names></name><name><surname>Thompson</surname><given-names>PL</given-names></name><etal>et al.</etal></person-group>
<article-title>Circulating adiponectin levels associate with inflammatory
markers, insulin resistance and metabolic syndrome independent of
obesity</article-title>. <source>Int J Obes (Lond)</source>
<year>2008</year>; <volume>32</volume>:
<fpage>772</fpage>&#x02013;<lpage>779</lpage>.<pub-id pub-id-type="pmid">18253163</pub-id></mixed-citation></ref><ref id="bibr44-2047487318790722"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega Moreno</surname><given-names>L</given-names></name><name><surname>Copetti</surname><given-names>M</given-names></name><name><surname>Fontana</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Evidence of a causal relationship between high serum adiponectin
levels and increased cardiovascular mortality rate in patients with type 2
diabetes</article-title>. <source>Cardiovasc Diabetol</source>
<year>2016</year>; <volume>15</volume>:
<fpage>17</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">26817832</pub-id></mixed-citation></ref><ref id="bibr45-2047487318790722"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Luis</surname><given-names>DA</given-names></name><name><surname>Izaola</surname><given-names>O</given-names></name><name><surname>de la Fuente</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<article-title>rs1501299 Polymorphism in the adiponectin gene and their
association with total adiponectin levels, insulin resistance and metabolic
syndrome in obese subjects</article-title>. <source>Ann Nutr Metab
[Internet]</source>
<year>2016</year>; <volume>69</volume>: <fpage>226</fpage>&#x02013;<lpage>231</lpage>.
<comment><ext-link ext-link-type="uri" xlink:href="www.karger.com/?doi=10.1159/000453401">www.karger.com/?doi=10.1159/000453401</ext-link> (accessed 9 July
2018)</comment>.</mixed-citation></ref><ref id="bibr46-2047487318790722"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gencer</surname><given-names>B</given-names></name><name><surname>Auer</surname><given-names>R</given-names></name><name><surname>de Rekeneire</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<article-title>Association between resistin levels and cardiovascular disease
events in older adults: the Health, Aging and Body composition
study</article-title>. <source>Atherosclerosis</source>
<year>2016</year>; <volume>245</volume>:
<fpage>181</fpage>&#x02013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">26724528</pub-id></mixed-citation></ref><ref id="bibr47-2047487318790722"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>KK</given-names></name><name><surname>Quon</surname><given-names>MJ</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name><etal>et al.</etal></person-group>
<article-title>Distinct vascular and metabolic effects of different classes of
anti-hypertensive drugs</article-title>. <source>Int J Cardiol</source>
<year>2010</year>; <volume>140</volume>:
<fpage>73</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">19059660</pub-id></mixed-citation></ref><ref id="bibr48-2047487318790722"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>Z</given-names></name><name><surname>Magkos</surname><given-names>F</given-names></name></person-group>
<article-title>Lean, but not healthy: the &#x0201c;metabolically obese,
normal-weight&#x0201d; phenotype</article-title>. <source>Curr Opin Clin Nutr Metab
Care</source>
<year>2016</year>; <volume>19</volume>:
<fpage>408</fpage>&#x02013;<lpage>417</lpage>.<pub-id pub-id-type="pmid">27552473</pub-id></mixed-citation></ref></ref-list></back></article>